Evaluating Multiple Dosing Regimens for Proton Pump Inhibitors (PPI) for Concerns the Treatment of Gastroesophageal Reflux Disease (GERD): Singi **Systematic Review and Meta-Analysis**

¹ Cancer Research Center for Health Equity, Cedars-Sinai Medical Center, Los Angeles CA *Co-first authors; **Co-senior authors

Introduction

- Several PPI dosing options are used to treat GERD with respect to dose (standard, half standard, double standard) and frequency (once or twice daily).
- We performed a systematic review to assess resolution of GERD symptoms, resolution of heartburn, and esophageal healing in regard to various PPI dosages and frequencies.

Methods

- EMBASE and PubMed Search in October 2021 yielded 1381 unique records. (Figure 1)
- 51 studies were included in the systematic review, and 37 RCTs were included in the quantitative analysis
- Primary outcomes: resolution of GERD symptoms, resolution of heartburn, esophageal healing ≤ 12 weeks.
- Data abstraction and analysis was performed using Systematic Review Data Repository+, Cochrane Risk of Bias tool (v2), and Stata (Figure 2).
- Studies were excluded from quantitative review if they did not report outcomes of interest, only assessed outcomes after 12 weeks, or compared out-of-practice dosages




Figure 1: Study Flow Chart


Katherine Barnhill^{1*}, BS; Tyra Nguyen^{1*}, BS; Alex Zhornitskiy, MD; Kyung Sang Yu, MD/PhD¹; Garth Fuller, MS¹; Katherine Makaroff, BS¹; Brennan Spiegel, MD, MSHS^{1**}; Gillian Gresham, PhD^{1*}

Results

- (Figure 3).

GERD symptoms (3A) and Heartburn (3B)

Drug and Study	Dosing	w				
	Dooling					
Dexlansoprazole						
Fass	30mg qd vs 60mg qd 0.0%, p = .)					
Subgroup, DL ($I^2 = 10$	00.0%, p = .)					
Esomeprazole						
Eggleston	20mg qd vs 40mg qd					
Subgroup, DL ($I^2 = 0$.	0%, p = .)					
Esomperazole						
Orlando	20mg qd vs 40mg qd					
Johnson	20mg qd vs 40mg qd					
Kahrilas	hrilas 20mg qd vs 40mg qd					
Subgroup, DL ($I^2 = 0$.)	0%, p = 0.369)					
Heterogeneity betwee Overall, DL ($I^2 = 0.0\%$						
Drug and						
Study	Dosing	W				
Lansonrazole						
Lansoprazole	30ma ad vs 60ma ad					
Lansoprazole Lee Subgroup, DL (I ² = 0.	30mg qd vs 60mg qd 0%, p = .)					
Lee Subgroup, DL (I ² = 0.						
Lee Subgroup, DL (I ² = 0. Pantoprazole	0%, p = .)					
Lee Subgroup, DL (I ² = 0. Pantoprazole Moretzsohn	0%, p = .) 20mg qd vs 40mg qd					
Lee Subgroup, DL (I ² = 0. Pantoprazole Moretzsohn Bochenek	0%, p = .) 20mg qd vs 40mg qd 20mg qd vs 40mg qd					
Lee Subgroup, DL (I ² = 0. Pantoprazole Moretzsohn Bochenek Richter	0%, p = .) 20mg qd vs 40mg qd 20mg qd vs 40mg qd 20mg qd vs 40mg qd					
Lee Subgroup, DL (I ² = 0. Pantoprazole Moretzsohn Bochenek	0%, p = .) 20mg qd vs 40mg qd 20mg qd vs 40mg qd 20mg qd vs 40mg qd					
Lee Subgroup, DL (l ² = 0. Pantoprazole Moretzsohn Bochenek Richter	0%, p = .) 20mg qd vs 40mg qd 20mg qd vs 40mg qd 20mg qd vs 40mg qd					
Lee Subgroup, DL (I ² = 0. Pantoprazole Moretzsohn Bochenek Richter Subgroup, DL (I ² = 0.	0%, p = .) 20mg qd vs 40mg qd 20mg qd vs 40mg qd 20mg qd vs 40mg qd					
Lee Subgroup, DL (I ² = 0. Pantoprazole Moretzsohn Bochenek Richter Subgroup, DL (I ² = 0.	0%, p = .) 20mg qd vs 40mg qd 20mg qd vs 40mg qd 20mg qd vs 40mg qd 0%, p = 0.987) 20mg qd vs 40mg qd					
Lee Subgroup, DL $(I^2 = 0.$ Pantoprazole Moretzsohn Bochenek Richter Subgroup, DL $(I^2 = 0.$ Omeprazole Laursen	0%, p = .) 20mg qd vs 40mg qd 20mg qd vs 40mg qd 20mg qd vs 40mg qd 0%, p = 0.987) 20mg qd vs 40mg qd					
Lee Subgroup, DL ($I^2 = 0$. Pantoprazole Moretzsohn Bochenek Richter Subgroup, DL ($I^2 = 0$. Omeprazole Laursen Subgroup, DL ($I^2 = 10$	0%, p = .) 20mg qd vs 40mg qd 20mg qd vs 40mg qd 20mg qd vs 40mg qd 0%, p = 0.987) 20mg qd vs 40mg qd					
Lee Subgroup, DL ($l^2 = 0$. Pantoprazole Moretzsohn Bochenek Richter Subgroup, DL ($l^2 = 0$.) Omeprazole Laursen Subgroup, DL ($l^2 = 10$ Rabeprazole	0%, p = .) 20mg qd vs 40mg qd 20mg qd vs 40mg qd 20mg qd vs 40mg qd 0%, p = 0.987) 20mg qd vs 40mg qd 00.0%, p = .) 20 mg qd vs 40mg qd					
Lee Subgroup, DL $(l^2 = 0.1)^2$ Pantoprazole Moretzsohn Bochenek Richter Subgroup, DL $(l^2 = 0.1)^2$ Omeprazole Laursen Subgroup, DL $(l^2 = 10)^2$ Rabeprazole Cloud	0%, p = .) 20mg qd vs 40mg qd 20mg qd vs 40mg qd 20mg qd vs 40mg qd 0%, p = 0.987) 20mg qd vs 40mg qd 00.0%, p = .) 20 mg qd vs 40mg qd 0%, p = .)					
Lee Subgroup, DL $(l^2 = 0.1)$ Pantoprazole Moretzsohn Bochenek Richter Subgroup, DL $(l^2 = 0.1)$ Omeprazole Laursen Subgroup, DL $(l^2 = 10)$ Rabeprazole Cloud Subgroup, DL $(l^2 = 0.1)$	0%, p = .) 20mg qd vs 40mg qd 20mg qd vs 40mg qd 20mg qd vs 40mg qd 0%, p = 0.987) 20mg qd vs 40mg qd 0.0%, p = .) 20 mg qd vs 40mg qd 0%, p = .) en groups: p = 0.132					
Lee Subgroup, DL $(I^2 = 0.1)^2$ Pantoprazole Moretzsohn Bochenek Richter Subgroup, DL $(I^2 = 0.1)^2$ Omeprazole Laursen Subgroup, DL $(I^2 = 10)^2$ Rabeprazole Cloud Subgroup, DL $(I^2 = 0.1)^2$	0%, p = .) 20mg qd vs 40mg qd 20mg qd vs 40mg qd 20mg qd vs 40mg qd 0%, p = 0.987) 20mg qd vs 40mg qd 0.0%, p = .) 20 mg qd vs 40mg qd 0%, p = .) en groups: p = 0.132					
Lee Subgroup, DL $(I^2 = 0.1)^2$ Pantoprazole Moretzsohn Bochenek Richter Subgroup, DL $(I^2 = 0.1)^2$ Omeprazole Laursen Subgroup, DL $(I^2 = 10)^2$ Rabeprazole Cloud Subgroup, DL $(I^2 = 0.1)^2$	0%, p = .) 20mg qd vs 40mg qd 20mg qd vs 40mg qd 20mg qd vs 40mg qd 0%, p = 0.987) 20mg qd vs 40mg qd 0.0%, p = .) 20 mg qd vs 40mg qd 0%, p = .) en groups: p = 0.132					



Acknowledgements: Ironwood Pharmaceuticals						
I: Dosing Comparisons across RCTs (≤12 weeks)						
<u>ng Comparison</u>	<u>RCTs (N)</u>	<u>Patients</u> (n)	<u>Outcome</u>	<u>OR (95% CI)</u>		
ndard dose BID vs. ard dose QD (ref)	1	202	Esophageal Healing	2.34 (1.27, 4.31) *		
	1	202	Heartburn	3.03 (1.62, 5.68) *		
standard dose QD	7	2408	Esophageal Healing	1.62 (1.27, 2.07) *		
vs. ard dose QD (ref)	6	1312	GERD	1.35 (1.05, 1.75) *		
	5	3433	Heartburn	1.08 (0.94, 1.24)		
standard dose, BID vs. ard dose QD (ref)	1	197	Heartburn	0.77 (0.44, 1.35)		
ndard dose QD vs.	9	1762	Esophageal Healing	1.79 (1.44, 2.22) *		
ndard dose QD (ref)	8	1718	GERD	1.42 (1.15, 1.76) *		
	14	3327	Heartburn	1.41 (1.17, 1.69) *		
ndard dose QD vs. ndard dose BID (ref)	2	411	Esophageal Healing	1.94 (1.15, 3.26) *		
	1	205	Heartburn	2.14 (1.19, 3.85) *		
standard dose BID vs. standard dose QD	1	190	Heartburn	0.90 (0.51, 1.60)		
(ref)	1	200	GERD	2.63 (1.30, 5.35) *		
ndard dose BID vs. ndard dose BID (ref)	1	202	Esophageal Healing	0.92 (0.47, 1.79)		
	1	203	Heartburn	1.42 (0.74, 2.74)		
tandard dose, BID vs. ndard dose QD (ref)	1	324	Esophageal Healing	7.43 (3.81, 14.49) *		

Conclusions

Increasing daily PPI dosing was generally associated with improved outcomes in the treatment of GERD symptoms.

• Further studies are needed to determine whether twice-daily dosing, a common practice used in clinical practice, improves clinical outcomes.